Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by 19F-Magnetic Resonance Imaging (MRI)

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Weibel, Stephanie ^a   Basse Luesebrink, Thomas Christian ^a,b   Hess, Michael ^a   Hofmann, Elisabeth ^a   Seubert, Carolin ^a   Langbein Laugwitz, Johanna ^a   Gentschev, Ivaylo ^a,e   Sturm, Volker Jörg Friedrich ^a   Ye, Yuxiang ^a   Kampf, Thomas ^a   Jakob, Peter Michael ^a,b   Szalay, Aladar A ^a,c,d,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Research Center for Magnetic Resonance Bavaria eV   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^e GENELUX CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; FLUOROCARBON; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL DENSITY; CONTROLLED STUDY; FEMALE; FLUORINE NUCLEAR MAGNETIC RESONANCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE QUALITY; IMMUNE RESPONSE; MACROPHAGE; MELANOMA; MOUSE; NANOEMULSION; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTON NUCLEAR MAGNETIC RESONANCE; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLUOROCARBONS; GENETIC VECTORS; HUMANS; INFLAMMATION; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MICE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SPATIO-TEMPORAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; VACCINIA VIRUS;

EID: 84874187438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056317     Document Type: Article

References (46)

1. Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, et al. (2011) The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 37: 618-632.
2. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, et al. (2010) Recent advances in cancer therapy: an overview. Curr Pharm Des 16: 3-10.
3. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE, (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
4. Parato KA, Senger D, Forsyth PA, Bell JC, (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
5. Liu TC, Galanis E, Kirn D, (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117.
6. Rowan K, (2010) Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst 102: 590-595.
7. Russell SJ, Peng KW, Bell JC, (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
8. Weibel S, Raab V, Yu YA, Worschech A, Wang E, et al. (2011) Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 11: 68.
9. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, et al. (2007) Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 67: 9398-9406.
10. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, et al. (2006) Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103: 12873-12878.
11. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, et al. (2009) The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
12. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, et al. (2008) Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 8: 1581-1588.
13. Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, et al. (2008) In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 118: 140-148.
14. Flogel U, Su S, Kreideweiss I, Ding Z, Galbarz L, et al. (2011) Noninvasive detection of graft rejection by in vivo (19) F MRI in the early stage. Am J Transplant 11: 235-244.
15. Ebner B, Behm P, Jacoby C, Burghoff S, French BA, et al. (2010) Early assessment of pulmonary inflammation by 19F MRI in vivo. Circ Cardiovasc Imaging 3: 202-210.
16. Kadayakkara DK, Ranganathan S, Young WB, Ahrens ET, (2012) Assaying macrophage activity in a murine model of inflammatory bowel disease using fluorine-19 MRI. Lab Invest 92: 636-645.
17. Weise G, Basse-Luesebrink TC, Wessig C, Jakob PM, Stoll G, (2011) In vivo imaging of inflammation in the peripheral nervous system by (19)F MRI. Exp Neurol 229: 494-501.
18. Hertlein T, Sturm V, Kircher S, Basse-Lusebrink T, Haddad D, et al. (2011) Visualization of abscess formation in a murine thigh infection model of Staphylococcus aureus by 19F-magnetic resonance imaging (MRI). PLoS One 6: e18246.
19. Temme S, Bonner F, Schrader J, Flogel U, (2012) (19) F magnetic resonance imaging of endogenous macrophages in inflammation. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4: 329-343.
20. Stoll G, Basse-Lusebrink T, Weise G, Jakob P (2012) Visualization of inflammation using (19) F-magnetic resonance imaging and perfluorocarbons. Wiley Interdiscip Rev Nanomed Nanobiotechnol.
21. Miller JC, Thrall JH, (2004) Clinical molecular imaging. J Am Coll Radiol 1: 4-23.
22. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, et al. (2006) In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48: 1818-1824.
23. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, et al. (2007) Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13: 636-641.
24. Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, et al. (2009) In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med 62: 747-753.
25. de Visser KE, Eichten A, Coussens LM, (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
26. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
27. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
28. Heusinkveld M, van der Burg SH, (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9: 216.
29. Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, et al. (2012) Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res 18: 2579-2590.
30. Gentschev I, Muller M, Adelfinger M, Weibel S, Grummt F, et al. (2011) Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 6: e22069.
31. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, et al. (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046.
32. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, et al. (2008) Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 68: 122-131.
33. Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, et al. (1993) A novel model of a metastatic human breast tumour xenograft line. Br J Cancer 68: 274-276.
34. Greer S, Alvarez M, Mas M, Wozniak C, Arnold D, et al. (2001) Five-chlorodeoxycytidine, a tumor-selective enzyme-driven radiosensitizer, effectively controls five advanced human tumors in nude mice. Int J Radiat Oncol Biol Phys 51: 791-806.
35. Gudbjartsson H, Patz S, (1995) The Rician distribution of noisy MRI data. Magn Reson Med 34: 910-914.
36. Lewis CE, Pollard JW, (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
37. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, et al. (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70: 5728-5739.
38. Morchel P, Melkus G, Yaromina A, Zips D, Baumann M, et al. (2010) Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. Radiother Oncol 96: 123-130.
39. Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, et al. (2011) Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer Res 17: 4484-4493.
40. Fang J, Nakamura H, Maeda H, (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63: 136-151.
41. Donat U, Weibel S, Hess M, Stritzker J, Hartl B, et al. (2012) Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice. PLoS One 7: e45942.
42. Soehnlein O, Lindbom L, (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10: 427-439.
43. Bingle L, Brown NJ, Lewis CE, (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
44. Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, et al. (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17: 5695-5704.
45. Meadowcroft MD, Zhang S, Liu W, Park BS, Connor JR, et al. (2007) Direct magnetic resonance imaging of histological tissue samples at 3.0T. Magn Reson Med 57: 835-841.
46. Thorne SH, (2011) Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 50: 286-293.